NASDAQ:MBRX Moleculin Biotech (MBRX) Stock Price, News & Analysis $3.52 +0.10 (+2.92%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.36▼$3.6150-Day Range$3.25▼$5.0152-Week Range$3.21▼$15.75Volume9,412 shsAverage Volume13,915 shsMarket Capitalization$8.13 millionP/E RatioN/ADividend YieldN/APrice Target$35.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Moleculin Biotech alerts: Email Address Moleculin Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside894.3% Upside$35.00 Price TargetShort InterestHealthy0.96% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($8.79) to ($5.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.22 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMoleculin Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageMoleculin Biotech has received no research coverage in the past 90 days.Read more about Moleculin Biotech's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.96% of the float of Moleculin Biotech has been sold short.Short Interest Ratio / Days to CoverMoleculin Biotech has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Moleculin Biotech has recently decreased by 28.67%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMoleculin Biotech does not currently pay a dividend.Dividend GrowthMoleculin Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MBRX. Previous Next 3.3 News and Social Media Coverage News SentimentMoleculin Biotech has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Moleculin Biotech this week, compared to 1 article on an average week.Search Interest1 people have searched for MBRX on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Moleculin Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.70% of the stock of Moleculin Biotech is held by insiders.Percentage Held by InstitutionsOnly 15.52% of the stock of Moleculin Biotech is held by institutions.Read more about Moleculin Biotech's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Moleculin Biotech are expected to grow in the coming year, from ($8.79) to ($5.28) per share.Price to Book Value per Share RatioMoleculin Biotech has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Moleculin Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad The Oxford ClubDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research... But today, the author of Get Rich with Dividends is feeling extra generous...Click here now to claim your FREE copy of Marc's AI playbook. About Moleculin Biotech Stock (NASDAQ:MBRX)Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.Read More MBRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MBRX Stock News HeadlinesJuly 25 at 5:34 AM | americanbankingnews.comMoleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.comJuly 10, 2024 | prnewswire.comMoleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AMLJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…June 14, 2024 | prnewswire.comMoleculin Announces Additional Positive Preliminary Interim Data from AML Clinical TrialJune 12, 2024 | prnewswire.comMoleculin to Present at the Virtual Investor Pitch ConferenceJune 5, 2024 | prnewswire.comMoleculin to Participate in the Virtual Investor Lunch Break SeriesMay 16, 2024 | prnewswire.comMoleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid CongressMay 15, 2024 | prnewswire.comMoleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)July 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…May 14, 2024 | msn.comMoleculin Biotech, Inc. (NASDAQ:MBRX) Q1 2024 Earnings Call TranscriptMay 14, 2024 | finance.yahoo.comMoleculin Biotech Inc (MBRX) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...May 13, 2024 | finanznachrichten.deMoleculin Biotech, Inc.: Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 13, 2024 | prnewswire.comMoleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 10, 2024 | investorplace.comMBRX Stock Earnings: Moleculin Biotech Beats EPS for Q1 2024May 10, 2024 | markets.businessinsider.comMoleculin Biotech’s Annamycin Shows Promising Efficacy in AML Treatment, Backed by Strong Clinical Results and Buy RatingMay 9, 2024 | prnewswire.comMoleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for AnnamycinMay 8, 2024 | prnewswire.comMoleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and WebcastMay 7, 2024 | prnewswire.comMoleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject DataSee More Headlines Receive MBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Moleculin Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today7/27/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MBRX CUSIPN/A CIK1659617 Webwww.moleculin.com Phone(713) 300-5160FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$35.00 High Stock Price Target$45.00 Low Stock Price Target$20.00 Potential Upside/Downside+894.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-29,770,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-87.19% Return on Assets-68.91% Debt Debt-to-Equity RatioN/A Current Ratio3.51 Quick Ratio3.51 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.70 per share Price / Book0.30Miscellaneous Outstanding Shares2,310,000Free Float2,157,000Market Cap$8.13 million OptionableNot Optionable Beta1.84 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Walter V. Klemp (Age 64)Founder, Chairman, President & CEO Comp: $894.54kMr. Jonathan P. Foster CPA (Age 60)Executive VP & CFO Comp: $611.17kDr. Donald H. Picker Ph.D. (Age 78)Chief Scientific Officer Comp: $486.44kDr. Waldemar Priebe Ph.D.Co-Founder, Founding Scientist & Chairman of Scientific Advisory BoardDr. John Paul Waymack M.D. (Age 72)Sc.D., Senior Chief Medical Officer Dr. Sandra L. Silberman M.D. (Age 69)Ph.D., Chief Medical Officer of New Products Dr. Wolfram C. M. Dempke M.B.A.M.D., Ph.D., European Chief Medical OfficerMs. Jacqueline Northcut (Age 62)Consultant Comp: $51.11kMr. Louis Ploth Jr. (Age 70)Independent Advisor Comp: $118.49kMore ExecutivesKey CompetitorsVaccinexNASDAQ:VCNXAkari TherapeuticsNASDAQ:AKTXEquilliumNASDAQ:EQDaré BioscienceNASDAQ:DAREVYNE TherapeuticsNASDAQ:VYNEView All CompetitorsInsidersWalter V KlempBought 12,560 shares on 12/26/2023Total: $129,996.00 ($10.35/share)Jonathan P FosterBought 1,932 shares on 12/26/2023Total: $19,996.20 ($10.35/share)Robert E GeorgeBought 966 shares on 12/26/2023Total: $9,998.10 ($10.35/share)View All Insider Transactions MBRX Stock Analysis - Frequently Asked Questions How have MBRX shares performed this year? Moleculin Biotech's stock was trading at $12.8760 at the beginning of 2024. Since then, MBRX stock has decreased by 72.7% and is now trading at $3.52. View the best growth stocks for 2024 here. How were Moleculin Biotech's earnings last quarter? Moleculin Biotech, Inc. (NASDAQ:MBRX) announced its quarterly earnings data on Friday, May, 10th. The company reported ($2.02) earnings per share for the quarter, beating analysts' consensus estimates of ($3.59) by $1.57. When did Moleculin Biotech's stock split? Shares of Moleculin Biotech reverse split before market open on Friday, March 22nd 2024. The 1-15 reverse split was announced on Friday, March 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, March 22nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Moleculin Biotech? Shares of MBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Moleculin Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Moleculin Biotech investors own include Inovio Pharmaceuticals (INO), Rite Aid (RAD), VBI Vaccines (VBIV), Gilead Sciences (GILD), Novavax (NVAX), Co-Diagnostics (CODX) and Dynavax Technologies (DVAX). This page (NASDAQ:MBRX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.